Valeant's (VRX) SEC Correspondence Shows Potential Problems With Tax Accounting, Adjusted Earnings Metrics - Wells Fargo
Tweet Send to a Friend
Wells Fargo reiterated an Underperform rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $10-$13. Analyst David Maris ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
